• Home
• Responsibility
• Our values and policies
• Environment, health and safety
• Management framework
• Management organisation
• Governance organisation

Governance organisation

GlaxoSmithKline has several groups that identify governance and ethical issues, recommend ways to manage them and periodically review the management of the issues. Environment, Health and Safety (EHS) issues are among those reviewed and addressed by these groups.

The Risk Oversight and Compliance Council (ROCC) is responsible for co-ordinating the internal control and risk management activities of the company. EHS is identified as one of the areas of the business that has the potential for serious adverse consequences if not managed properly.

The Corporate Executive Team (CET) actively manages EHS issues. Andrew Witty has identified himself as the champion of environment, health and safety for both the CET and the Board. He ensures that EHS issues are regularly debated to verify that we are pursuing responsible programmes for all operations.  The General Counsel is the operational champion of EHS on the CET.  The Vice President, Corporate Environment, Health and Safety reports at least annually to the CET on EHS issues.

The Board of Directors has two committees that evaluate the management and effectiveness of our EHS programme. These mechanisms for review and oversight provide opportunities for environment, health and safety issues to be considered at the highest level of the organisation.

The Audit Committee of the Board reviews EHS performance to confirm that issues are properly managed and controlled. The Vice President, Corporate Environment, Health and Safety makes annual presentations to the Audit Committee so that they can review measures of environment, health and safety performance and track our progress toward meeting EHS targets. They also review the results of EHS audits of GlaxoSmithKline operations, contract manufacturers and key suppliers. The level of scrutiny of the Audit Committee is in line with requirements of Sarbanes-Oxley.

The Corporate Responsibility Committee advises the Board on social, ethical and environmental issues that have the potential to seriously impact GlaxoSmithKline’s business and reputation. The Vice President, Corporate Environment, Health and Safety provides reports to this committee on aspects of EHS, such as sustainability, that have social implications above strict regulatory compliance.

Back to top